Board-certified dermatologist and former Drexel Associate Professor. Internationally recognized expertise in skin cancer developing in organ transplant recipients with groundbreaking publications identifying key risk factors in patients of color. Dr. Chung's work provides extensive experience with mTOR inhibitors. She is co-author of the 2019 Geroscience study demonstrating that topical rapamycin reduces markers of cellular aging in human skin. Dr. Chung helped establish the clinical evidence that makes longevity science credible in dermatology. At Hayflick, she leads with the same discipline she brings to her research: no hype, no shortcuts, no apology for the ambition.

Professor at Drexel University and director of its Aging Initiative. For more than fifteen years, he has studied the biological boundary where cells stop dividing, and what it would take to extend it. Dr. Sell’s research in mTOR biology forms a foundational pillar of Hayflick’s scientific strategy. At Hayflick, he applies deep mechanistic expertise to translate cellular aging science into measurable therapeutic progress.

With a background in executive leadership at Tiffany & Co. and Cartier, Bernadette brings deep experience building globally trusted luxury brands. She specializes in aligning operations, narrative, and execution at scale – an expertise she recently applied to the indie beauty sector, where she professionalized a growth start-up’s operations and sharpened its premium identity for commercial scale. At Hayflick, Bernadette translates complex science into strategic clarity—building the partnerships, structure, and positioning required for long-term growth.

Biotech executive and intellectual property attorney with extensive experience in biotech and pharmaceutical IP and licensing strategy, ANDA litigation and lifecycle management. Mike has guided therapeutics through complex commercial and legal landscapes, protecting innovation and enabling durable partnerships. At Hayflick, he ensures that breakthrough biology is strategically protected and positioned for sustained value creation.

Board-certified dermatologist and fellowship-trained Mohs micrographic surgeon with over fifteen years of experience in dermatologic surgery and aesthetic dermatology. She trained at UCSF and served on faculty for twelve years, leading translational skin cancer research and holding senior clinical leadership roles. At Hayflick, she provides guidance on dermatologic strategy and the clinical integration of emerging therapeutics.

Biologist and biogerontologist widely recognized for pioneering research on evolutionarily conserved mechanisms of aging. Matt is the founder and CEO of Optispan, a proactive health platform focused on science-based preventative medicine, and Co-Director of the Dog Aging Project, one of the largest longitudinal studies of aging in companion animals. His work explores how longevity interventions influence healthspan across species. At Hayflick, he provides scientific guidance on aging biology and the translation of longevity research into clinical applications.

Distinguished Professor at the National University of Singapore and Director of the Centre for Healthy Longevity. He previously served as President and CEO of the Buck Institute for Research on Aging, one of the world’s leading institutions in aging science. His work focuses on translating longevity research into measurable human health outcomes. At Hayflick, he provides strategic guidance on translational science and long-term scientific direction.

Pharmaceutical development scientist with over twenty-five years of experience in FDA submissions, CMC and regulatory strategy. Dr. Calias has navigated the path from compound to approval across multiple therapeutic modalities. At Hayflick, he ensures that scientific ambition is matched by regulatory precision and executional reality.